Australian Based, Cannim executes Jamaica’s first ganja export to Germany.

Australian-headquartered medicinal ganja company Cannim has announced the completion of the first-ever legal commercial export of Jamaican ganja flower to Germany.

Germany is the one of the world’s most significant medicinal ganja markets, and Cannim’s Chief Commercial Officer Stuart Marsh said this announcement was a key step towards achieving Cannim’s mission to become a global leader in the medicinal and wellness ganja sectors.

“Germany represents a huge opportunity for Cannim, and our ability to cultivate high-quality, medical grade Jamaican ganja that meets the strict standards of the German Pharmacopoeia is testament to the professionalism of our teams in Jamaica and Australia,” Marsh said.

“The support we have received from all levels of the Jamaican Government and its agencies and the rigour of Jamaica’s Cannabis Licensing Authority (CLA) in ensuring Jamaica’s industry complies with international treaty obligations have been essential in securing Jamaica’s entry to this global arena.”

Stuart acknowledged the Government and CLA’s willingness to expedite the improvement of interim regulations and timely processes to drive Jamaica’s ability to effectively compete on the world stage. Minister of Industry, Investment and Commerce Audley Shaw said the move is a landmark achievement.

“Jamaica has long had a rich history with ganja and we are proud to have been able to support the industry and Cannim in achieving this pioneering export to Germany,” said Shaw.

“We are excited to finally be able to start satisfying global demand for the finest Jamaican-grown medicinal ganja products,” he continued.

The initial shipment of high-THC ganja flowers was grown on Cannim’s 500-acre farm in Jamaica, representing the first batch of an ongoing supply, with significant quantities of the product ready to be released into Germany over the coming months.

Cannim has formed a strong partnership with Cantourage, one of Europe’s leading medical ganja companies, and will use Cantourage’s “Fast Track Access” platform to enter European medical markets.

CEO of Cantourage Philip Schetter said, “this is an exciting milestone for the rapidly expanding medicinal ganja sector in Germany. The local market has been growing for some time, but this is the first time we have been able to supply the highest quality products processed from genuine Jamaican ganja flower. Cantourage places great value on natural products which amplify the benefits for German patients, and this partnership opens up access to a new source with an established reputation for ideal growing conditions… our partnership with Cannim offers us an unprecedented opportunity to bring medical ganja from Jamaica, which is known for its ideal growing conditions, into the fast-growing European medical ganja market for the first time.”